Drug Trial Radar · NCT06625931
Clinical Trial to Evaluate the Safety and Efficacy of NTCB01-1 in Patients Who Require Parenteral Nutrition
Last checked: Nov 19, 2026Latest source record: May 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
60
Actual
Start
Nov 14, 2024
Primary completion
Mar 28, 2025
Study completion Mar 28, 2025
Sponsor
- Lead sponsor
- Yuhan CorporationIndustry
- Sponsor type
- Industry
- First posted
- Oct 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 19 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Randomized, Open-labeled, Multi-center, Active-controlled, Parallel-group Phase 3 Clinical Trial to Evaluate the Safety and Efficacy of NTCB01-1 versus NTCB-P in patients who require parenteral nutrition
Conditions
- Parenteral Nutrition
Interventions
NTCB01-1Drug
3 Days infusion
NTCB-PDrug
3 Days infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurance rate of adverse drug reactionTime frame: Day 1 to day 4
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Keimyung University Dongsan Hospital
Daegu, Dalseo-gu, South Korea
Seoul Metropolitan Government Seoul National University Boramae Medical Center
Seoul, Dongjak-gu, South Korea
Seoul National University Hospital
Seoul, Jongno-gu, South Korea
Kosin University Gospel Hospital
Busan, Seo-gu, South Korea
The Catholic University of Korea, Seoul ST. Mary's Hospital
Seoul, Seocho-Gu, South Korea
Korea University Anam Hospital
Seoul, Seongbuk-gu, South Korea
Ajou University Medical Center
Gyeonggi-do, Suwon-si, South Korea
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.